Source: Pharamceutical Technology

Zogenix: UCB concludes acquisition of biopharma firm Zogenix for $1.9bn

With the acquisition, UCB will add Fintepla to its current portfolio of products. The post UCB concludes acquisition of biopharma firm Zogenix for $1.9bn appeared first on Pharmaceutical Technology.

Read full article »

Zogenix's Competitors | Zogenix's News | Zogenix's Financials

Followers on Owler

222

Est. Annual Revenue

$25-100M

Est. Employees

250-500

President & CEO

Stephen J. Farr

CEO Approval Rating

84/100

Zogenix is a California-based biopharmaceutical company that develops and commercializes transformative therapies for the treatment of epilepsy and mitochondrial diseases.